EDIT
Editas Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.23
+4.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 47.0M | 40.5M | 32.3M | 78.1M | 19.7M |
| Cost of Revenue | 20.3M | — | 199.2M | 6.1M | 6.3M |
| Gross Profit | 26.7M | 40.5M | (166.9M) | 72.1M | 13.4M |
| Operating Expenses | |||||
| R&D Expense | 70.2M | 90.0M | 199.2M | 177.7M | 175.0M |
| SG&A Expense | 45.5M | 49.9M | 72.0M | 69.7M | 70.7M |
| General & Admin Expense | 45.5M | 49.9M | 72.0M | 69.7M | 70.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (6.8M) | — | (187.0M) | (6.1M) | (6.3M) |
| Total Operating Expenses | 108.9M | 139.9M | 84.2M | 241.2M | 239.3M |
| Cost and Expenses | 129.1M | 139.9M | 283.5M | 247.3M | 245.7M |
| Operating Income (EBIT) | (82.1M) | (99.3M) | (251.2M) | (169.2M) | (225.9M) |
| Non-Operating | |||||
| Interest Income | (3.6M) | 8.3M | 14.1M | 17.6M | 5.5M |
| Interest Expense | (2.1M) | 6.2M | — | — | — |
| Net Interest Income | (1.5M) | 2.1M | 14.1M | 17.6M | 5.5M |
| Other Non-Op Income/Expense | 8.2M | (60.7M) | 14.1M | 16.0M | 5.5M |
| Non-Operating Income (excl Interest) | (9.5M) | 54.6M | (12.2M) | (16.0M) | (5.5M) |
| EBT (Pre-Tax Income) | (73.9M) | (160.1M) | (237.1M) | (153.2M) | (220.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (73.9M) | (160.1M) | (237.1M) | (153.2M) | (220.4M) |
| Earnings from Cont. Ops | (73.9M) | (160.1M) | (237.1M) | (153.2M) | (220.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (73.9M) | (160.1M) | (237.1M) | (153.2M) | (220.4M) |
| Per Share | |||||
| Basic EPS | ($0.75) | ($1.80) | ($2.88) | ($2.02) | ($3.21) |
| Diluted EPS | ($0.75) | ($1.80) | ($2.88) | ($2.02) | ($3.21) |
| Revenue Per Share | $0.39 | $0.46 | $0.39 | $1.03 | $0.29 |
| Shares | |||||
| Basic Shares Outstanding | 119.3M | 88.7M | 82.3M | 76.0M | 68.7M |
| Diluted Shares Outstanding | 119.3M | 88.7M | 82.3M | 76.0M | 68.7M |
| Profitability Metrics | |||||
| EBITDA | (70.2M) | (148.6M) | (233.1M) | (147.2M) | (214.1M) |
| D&A | 2.4M | 5.3M | 5.8M | 6.1M | 6.3M |
| EBIT | (72.7M) | (153.9M) | (238.9M) | (153.2M) | (220.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026